Brought to you by 
Domain leads aTyr Pharma's $23mm Series C round
01 Dec 2010
Executive Summary
Domain Associates has led aTyr Pharma Inc.'s $23mm oversubscribed Series C venture round and will contribute one board member. It joins current shareholders Alta Partners, Cardinal Partners, and Polaris Ventures. The company will use the proceeds to continue developing its preclinical pipeline and move physiocrine drug candidates--which have potential to treat patients with blood, immune, and metabolic disorders--into clinical studies. ATyr Pharma has raised $46mm to date.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Domain leads aTyr Pharma's $23mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice